StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research report sent to investors on Friday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
Shares of NASDAQ NBRV opened at $0.00 on Friday. Nabriva Therapeutics has a 1 year low of $1.22 and a 1 year high of $8.45. The company has a debt-to-equity ratio of 0.12, a current ratio of 0.85 and a quick ratio of 0.52. The stock has a market cap of $6,403.00, a P/E ratio of 0.00 and a beta of 1.53.
Nabriva Therapeutics Company Profile
See Also
- Five stocks we like better than Nabriva Therapeutics
- Breakout Stocks: What They Are and How to Identify Them
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- What is a Death Cross in Stocks?
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- What Are Trending Stocks? Trending Stocks Explained
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.